Active, not recruitingPHASE1, PHASE2NCT05665166
Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type II
Studying Mucopolysaccharidosis type 1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Manchester
- Principal Investigator
- Robert WynnManchester Foundation Trust
- Intervention
- Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII(genetic)
- Enrollment
- 5 enrolled
- Eligibility
- MALE
- Timeline
- 2023 – 2028
Study locations (1)
- Manchester University Foundation Trust, Manchester, United Kingdom
Collaborators
CTI Clinical Trial and Consulting Services · Great Ormond Street Hospital for Children NHS Foundation Trust · Manchester University NHS Foundation Trust · LifeArc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05665166 on ClinicalTrials.govOther trials for Mucopolysaccharidosis type 1
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06488924An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIBJCR Pharmaceuticals Co., Ltd.
- RECRUITINGPHASE1NCT06519552A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type IWest China Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06181136Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)Denali Therapeutics Inc.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06095388Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIAJCR Pharmaceuticals Co., Ltd.
- ACTIVE NOT RECRUITINGNCT05634512Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.Masonic Cancer Center, University of Minnesota
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04201405Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIAUniversity of Manchester
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT03566043CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)REGENXBIO Inc.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03488394Gene Therapy With Modified Autologous Hematopoietic Stem Cells for the Treatment of Patients With Mucopolysaccharidosis Type I, Hurler VariantOrchard Therapeutics